Proteomic Signature in Breast Cancer: Correlation With Tumor Response to Neo-adjuvant Chemotherapy (SPAM)

Centre Oscar Lambret

Status: Completed

Conditions: Breast Cancer

Treatments: Procedure: Blood sampling; Procedure: SURGERY; Procedure: BIOPSY

Study type: Interventional

Funder types: Other

Identifiers

NCT00911911

SPAM 2006-10

Details and patient eligibility

About

The scope of the trial is to identify proteomic signatures correlated with tumor response to neo-adjuvant chemotherapy.

Enrollment: 66 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Women aged more than 18 years
• Histologically proven breast carcinoma
• Neo-adjuvant chemotherapy with anthracyclines and/or taxanes
• No prior chemotherapy
• Written informed consent

Exclusion criteria

• Metastatic disease

Trial design

66 participants in 1 patient group

FEC 100 + TAXOTERE

Experimental group

Description:

FEC 100 = Fluoro-uracile + Epirubicin + Cyclophosphamide Fluoro-uracile : 500 mg/m²/cycle Epirubicin : 100 mg/m²/cycle Cyclophosphamide : 500 mg/m²/cyle 1 cycle = 21 days. For a total of 6 cycles or 3 cycles followed by 3 cycles of TAXOTERE TAXOTERE 100 mg/m²/cycle 1 cycle = 21 days. For a total of 3 cycles following 3 FEC 100

Treatment:

Procedure: BIOPSY

Procedure: SURGERY

Procedure: Blood sampling